Publications by authors named "P J Guruprasad"
Introduction: Dermoscopy is an important noninvasive tool that helps to determine the stability and activity of vitiligo. Various dermoscopic findings help classify the disease as stable or unstable. This is important for the management of the disease, as surgical management requires disease stability.
View Article and Find Full Text PDFArticle Synopsis
- Many patients treated with FDA-approved CAR T cells see their disease progress, especially with solid cancers and certain types of blood cancers like T cell lymphomas.
- A major challenge in adoptive T cell therapies is the dysfunction of CAR T cells, which struggle to expand and last after being infused.
- The study reveals that knocking out the CD5 gene using CRISPR-Cas9 can improve the antitumor abilities of CAR T cells by enhancing their function and persistence, suggesting CD5 as a key target for improving T cell therapies.
A Comparative Study on Serum Levels of "Thymic Stromal Lymphopoietin" Between Patients with Psoriasis Vulgaris and Healthy Individuals: A Case-Control Study.
Siri Sri Kollabathula Konakanchi Venkatachalam Kethireddi Susmitha Divya Patnala Guruprasad Pallapati Anila Sunandini Nayar
Indian Dermatol Online J
April 2024
Background: Thymic stromal lymphopoietin (TSLP) is a cytokine initially implicated to be associated with allergic disorders inducing Th2 response. Emerging studies have shown that TSLP is also involved in autoimmune diseases. In psoriasis, TSLP acts in synergy with T cell-derived CD40L to promote the release of IL-23 from dendritic cells.
View Article and Find Full Text PDFArticle Synopsis
- - The study identifies the interaction between BTLA on T cells and HVEM on regulatory T cells as a major factor limiting the effectiveness of T cell-based immunotherapies in tumors.
- - High levels of BTLA in CAR T cells are linked to poorer treatment outcomes, prompting researchers to delete BTLA to improve the T cells' tumor-fighting abilities.
- - By removing BTLA, T cells show enhanced signaling and function, suggesting that targeting the BTLA-HVEM interaction could boost the success of CAR T cell therapies.